Proline cycle-mediated metabolic reprogramming in gemcitabine resistance of pancreatic cancer.

被引：0
|
作者：
Shen, Yu-Shiuan [1 ]
Huang, Ming-Te [1 ]
Su, Yan-Hao [1 ]
Su, Chih-Ming [1 ]
Chen, Hsin-An [1 ]
机构：
[1] Hosp Tokyo, Dept Surg, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PE14-3-2
引用
收藏
页码：760 / 760
页数：1
相关论文
共 50 条
  • [21] Markers of cell cycle-mediated drug resistance and prognosis of patients receiving preoperative combined modality therapy for rectal cancer
    Waldman, SA
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (11) : 949 - 950
  • [22] Linking metabolic reprogramming to therapy resistance in cancer
    Morandi, Andrea
    Indraccolo, Stefano
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2017, 1868 (01): : 1 - 6
  • [23] Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors
    Reyes-Castellanos, Gabriela
    Abdel Hadi, Nadine
    Carrier, Alice
    CELLS, 2022, 11 (03)
  • [24] Metabolic reprogramming of immune cells in pancreatic cancer progression
    Xiang, Hong
    Yang, Runjuan
    Tu, Jiaxin
    Xi, Yan
    Yang, Shilei
    Lv, Linlin
    Zhai, Xiaohan
    Zhu, Yanna
    Dong, Deshi
    Tao, Xufeng
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 157
  • [25] Phase II study of gemcitabine and Flutamide in advanced pancreatic cancer.
    Mayer, A
    Shaw, J
    D'Ath, S
    Price, P
    Blesing, C
    Corrie, P
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [26] Cd36 Mediated Metabolic Reprogramming in Cancer Stem Cells Contributes to Drug Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors
    Guo, Yichen
    Chen, Herbert
    Ren, Bin
    PANCREAS, 2022, 51 (03) : E31 - E32
  • [27] A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer.
    Xiong, HQ
    Hess, KR
    Kayaleh, OR
    Goodwin, JW
    Banerjee, T
    Sinclair, SS
    Fisch, MJ
    Wolff, RA
    Abbruzzese, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 351S - 351S
  • [28] Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.
    de Lange, SM
    van Groeningen, CJ
    Giaccone, G
    Pinedo, HM
    Meijer, OWM
    Langendijk, JA
    Slotman, BJ
    CLINICAL CANCER RESEARCH, 2000, 6 : 4540S - 4541S
  • [29] Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest
    Han, Bingjie
    Sun, Yuanyuan
    Zhang, Xiaofen
    Yue, Ping
    Tian, Meiling
    Yan, Dan
    Yin, Fanxiang
    Qin, Bo
    Zhao, Yi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Markers of Cell Cycle-Mediated Drug Resistance And Prognosis Of Patients Receiving Preoperative Combined Modality Therapy For Rectal Cancer
    Scott A. Waldman
    Annals of Surgical Oncology, 2004, 11 : 949 - 950
12345